Ipamorelin Side Effects and Safety

Safety & Tolerability

Ipamorelin's defining tolerability feature is selectivity: in its foundational pharmacology it stimulated growth-hormone release without meaningfully raising cortisol, prolactin, or ACTH, and without the appetite stimulation seen with other growth-hormone-releasing peptides — avoiding several of their characteristic side effects. Published human exposure is limited to pharmacokinetic/pharmacodynamic study and a completed Phase II trial; long-term human safety is not established. Human data: Human data comprises pharmacokinetic/pharmacodynamic study in volunteers and a completed Phase II trial for postoperative ileus (NCT00672074); ipamorelin's development for that indication was subsequently discontinued without approval, and no efficacy trials for growth-hormone deficiency, body composition, or anti-aging have been published. Long-term safety is uncharacterized. Regulatory status: Not approved for human use by any regulatory agency; available only as a research compound. Ipamorelin stimulated GH release without significantly increasing cortisol, prolactin, or ACTH at GH-releasing doses, and without the appetite stimulation of GHRP-6 — a selectivity profile that avoids several side effects associated with earlier growth-hormone-releasing peptides. Animal Ipamorelin stimulated GH release without significantly increasing cortisol, prolactin, or ACTH at GH-releasing doses, and without the appetite stimulation of GHRP-6 — a selectivity profile that avoids several side effects associated with earlier growth-hormone-releasing peptides. Ipamorelin advanced to a completed Phase II clinical trial for postoperative ileus (NCT00672074); its clinical development for that indication was later discontinued without regulatory approval. Human trial Ipamorelin advanced to a completed Phase II clinical trial for postoperative ileus (NCT00672074); its clinical development for that indication was later discontinued without regulatory approval.